Valuation : Caplin Point Laboratories Limited

Market Cap 21TCr 217.12Cr 187.29Cr 176.18Cr 160.5Cr 301.82Cr 303.45Cr 2.08TCr 810.65Cr 10TCr 815.19Cr 797.52Cr 35TCr P/E 2026
17.9x
P/E 2027 * 28.4x
Enterprise Value 21TCr 217.12Cr 187.29Cr 176.18Cr 160.5Cr 301.82Cr 303.45Cr 2.08TCr 810.65Cr 10TCr 815.19Cr 797.52Cr 35TCr EV / Sales 2026
5.23x
EV / Sales 2027 * 8.22x
Free-Float
26.56%
Yield 2026 *
-
Yield 2027 * 0.15%
1 day+0.14%
1 week+7.77%
Current month+7.84%
1 month+5.89%
3 months+36.65%
6 months+62.07%
Current year+47.44%
1 week 2,491.95
Extreme 2491.95
2,752.55
1 month 2,381
Extreme 2381
2,752.55
Current year 1,502.45
Extreme 1502.45
2,752.55
1 year 1,502.45
Extreme 1502.45
2,752.55
3 years 950
Extreme 950
2,752.55
5 years 575
Extreme 575
2,752.55
10 years 180
Extreme 180
2,752.55
Manager TitleAgeSince
Chief Executive Officer 71 28/03/2015
Director of Finance/CFO - 19/02/2016
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 27/01/2010
Director/Board Member - 05/11/2025
Director/Board Member 71 28/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%+7.77%+27.49%+153.64% 217.12Cr
+0.14%+1.70%+23.42%+74.20% 4.88TCr
-1.61%-0.29%+51.58%+118.38% 4.07TCr
-1.16%+0.37%+15.87%+86.01% 1.23TCr
-0.72%+0.72%-9.97%+14.04% 1.21TCr
+0.57%+1.73%+31.59%+153.11% 928.38Cr
-2.59%-4.06%+22.81%+42.89% 755.42Cr
-0.42%+0.89%+28.21%+223.05% 734.57Cr
-0.62%-0.84%+44.70%-11.26% 729.62Cr
-0.13%-0.16%-40.47%+15.85% 525.5Cr
Average -0.65%+1.90%+19.52%+86.99% 1.53TCr
Weighted average by Cap. -0.68%+1.37%+27.23%+87.59%

Financials

2026 2027 *
Net sales 2.13TCr 22Cr 19Cr 18Cr 17Cr 31Cr 31Cr 215.07Cr 84Cr 1.08TCr 84Cr 82Cr 3.59TCr 2.51TCr 26Cr 23Cr 21Cr 20Cr 37Cr 37Cr 253.41Cr 99Cr 1.28TCr 99Cr 97Cr 4.23TCr
Net income 616.2Cr 6.49Cr 5.6Cr 5.27Cr 4.8Cr 9.03Cr 9.07Cr 62Cr 24Cr 313.45Cr 24Cr 24Cr 1.04TCr 726.45Cr 7.65Cr 6.6Cr 6.21Cr 5.66Cr 11Cr 11Cr 73Cr 29Cr 369.53Cr 29Cr 28Cr 1.23TCr
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
3,966
Date Price Change Volume
02/26/02 2,714.70 +0.14% 17,888
01/26/01 ₹2,710.95 +7.69% 77,720
31/26/31 ₹2,517.25 +0.05% 5,166
28/26/28 ₹2,516.10 -1.02% 6,889
27/26/27 ₹2,542.15 +0.92% 7,325
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,710.95INR
Average target price
2,765.00INR
Spread / Average Target
+1.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPLIPOINT Stock